Threshold Pharmaceuticals focuses on discovering and developing drugs that target tumor hypoxia, a low oxygen condition found in solid tumors. Their approach selectively targets tumor cells, making their drug candidates potentially more effective and less toxic to healthy tissues compared to conventional anticancer drugs. Their initial clinical focus is on treating cancer and benign prostatic hyperplasia (BPH), a common disease in men. By leveraging metabolic targeting, Threshold Pharmaceuticals aims to provide broad potential for treating various solid tumors and certain other diseases.